Literature DB >> 2081926

A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer.

K Satake1, Y S Chung, H Yokomatsu, B Nakata, H Tanaka, T Sawada, H Nishiwaki, K Umeyama.   

Abstract

Many substances that are widely used as tumor markers for detecting pancreatic cancer are discussed. Some are good indicators, but some are not. Among them, CA 19-9 and SPan-1 have higher sensitivity and specificity for diagnosis of pancreatic cancer. However, these markers are neither tumor-specific nor pancreatic-cancer-specific. Accurate understanding of the measurement of serum tumor markers makes it possible for them to be useful adjunctive tools for detecting pancreatic cancer, even in small cancers, and for monitoring patients after treatment.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2081926     DOI： 10.1007/BF02924217

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN： 0169-4197


  20 in total

Review 1.  [Evaluation of monoclonal antibody to tumor-associated carbohydrate antigen for diagnosis of human cancer].

Authors:  M Ishii
Journal:  Tanpakushitsu Kakusan Koso       Date:  1988-05

2.  Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody.

Authors:  O Nilsson; J E Månsson; L Lindholm; J Holmgren; L Svennerholm
Journal:  FEBS Lett       Date:  1985-03-25       Impact factor: 4.124

3.  Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody.

Authors:  D M Mahvi; W C Meyers; R C Bast; H F Seigler; R S Metzgar
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

4.  Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer.

Authors:  F V Ona; N Zamcheck; P Dhar; T Moore; H Z Kupchik
Journal:  Cancer       Date:  1973-02       Impact factor: 6.860

5.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

6.  Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.

Authors:  P J Blind; S T Dahlgren
Journal:  Acta Chir Scand       Date:  1987-01

7.  Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.

Authors:  C Haglund; P Kuusela; H Jalanko; P J Roberts
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

8.  Value of ultrasonographic examination combined with measurement of serum tumor markers in the diagnosis of pancreatic cancer of less than 3 cm in diameter.

Authors:  H Iishi; H Yamamura; M Tatsuta; S Okuda; T Kitamura
Journal:  Cancer       Date:  1986-05-15       Impact factor: 6.860

9.  A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.

Authors:  K Satake; G Kanazawa; I Kho; Y S Chung; K Umeyama
Journal:  J Surg Oncol       Date:  1985-05       Impact factor: 3.454

10.  Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma.

Authors:  R S Metzgar; N Rodriguez; O J Finn; M S Lan; V N Daasch; P D Fernsten; W C Meyers; W F Sindelar; R S Sandler; H F Seigler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205
View more
  5 in total

1.  Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer.

Authors:  Yuki Sunagawa; Suguru Yamada; Yusuke Sato; Daishi Morimoto; Fuminori Sonohara; Hideki Takami; Yoshikuni Inokawa; Masamichi Hayashi; Mitsuro Kanda; Chie Tanaka; Daisuke Kobayashi; Goro Nakayama; Masahiko Koike; Michitaka Fujiwara; Tsutomu Fujii; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2019-10-30       Impact factor: 5.344

2.  Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers.

Authors:  Junko Umeda; Takao Itoi; Atsushi Sofuni; Fumihide Itokawa; Toshio Kurihara; Takayoshi Tsuchiya; Kentaro Ishii; Shujiro Tsuji; Nobuhito Ikeuchi; Reina Tanaka; Ryosuke Tonozuka; Mitsuyoshi Honjo; Shuntaro Mukai; Toshitaka Nagao; Hisashi Oshiro; Fuminori Moriyasu
Journal:  J Oncol       Date:  2013-12-18       Impact factor: 4.375

3.  MIR1246 in body fluids as a biomarker for pancreatic cancer.

Authors:  Fumitaka Ishige; Isamu Hoshino; Yosuke Iwatate; Satoshi Chiba; Hidehito Arimitsu; Hiroo Yanagibashi; Hiroki Nagase; Wataru Takayama
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

4.  Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma.

Authors:  Eramah Ermiah; Mona Eddfair; Othman Abdulrahman; Mohamed Elfagieh; Abdalla Jebriel; Mona Al-Sharif; Mourad Assidi; Abdelbaset Buhmeida
Journal:  Mol Clin Oncol       Date:  2022-06-16

Review 5.  Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis.

Authors:  Qingcai Meng; Si Shi; Chen Liang; Dingkong Liang; Wenyan Xu; Shunrong Ji; Bo Zhang; Quanxing Ni; Jin Xu; Xianjun Yu
Journal:  Onco Targets Ther       Date:  2017-09-15       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.